HOME >> MEDICINE >> NEWS
The Lancet Neurology press release

Although rabies kills more people every year (50 000 worldwide) than dengue virus, yellow fever, and Japanese encephalitis combined, it receives little attention and is at the bottom of the WHO's "top ten" of infectious diseases. A review in this month's TLN highlights the horrific clinical picture of rabies and covers the pathogenesis, diagnosis, and management of the disease.

This month's Leading Edge (Rabies: what can neurologists do?) outlines a number of ways in which neurologists can help both to reduce the number of rabies deaths and to ensure that more accurate epidemiological data can be obtained in the future.

The placebo effect in neurological disorders

Recent evidence suggests that the placebo effect is mediated by the dopaminergic reward mechanisms in the human brain and that it is related to the expectation of clinical benefit. On the basis of this theory, Raul de la Fuente-Fernndez, Michael Schulzer, and A Jon Stoessl (University of British Columbia, Vancouver, BC, Canada) review the evidence for a placebo effect in Parkinson's disease, depression, pain, and other neurological disorders. They also discuss the evidence for the use of placebos in long-term substitution programmes for the treatment of drug addiction.

Treatment of neural injury with marrow stromal cells

Michael Chopp and Yi Li (Henry Ford Health Sciences Center, Detroit, MI) describe their preclinical studies on the use of bone-marrow stromal cells in the treatment of neural injury. These cells have been transplanted directly into the brain or administered intra-arterially or intravenously. The authors conclude: "Given the robust therapeutic benefit of these cells in the treatment of neural injury, and the fact that marrow stromal cells have been used in the treatment of other human disease, there is justification for further preclinical studies leading to clinical trials for the treatment of neural injury such as stroke."


'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7424-4949
Lancet
15-May-2002


Page: 1

Related medicine news :

1. The Lancet calls for the creation of a world institute for risk evaluation
2. The Lancet calls for creation of Intl Commission on Global Responses to Complex Emergencies
3. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
4. The Lancet Oncology (TLO)
5. The Lancet Infectious Diseases (TLID)
6. The Lancet Neurology November press release
7. Lancet readers to join WHO election debate
8. The Lancet Oncology press release
9. The Lancet Neurology October press release
10. The Lancet neurology press release
11. The Lancet Neurology press release

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The Lancet Neurology press release

(Date:5/21/2013)... Paris, France: One-year results from SOURCE XT one ... registries to-date reported today at EuroPCR 2013 show ... rates of device success for all access approaches, valve ... Study followed up 2688 consecutively enrolled patients (mean age ... valve at 93 centres in 17 countries between July ...
(Date:5/21/2013)... stent, which is a novel stent platform eluting ... the Xience Prime everolimus-eluting stent for the primary ... nine months in the results of an imaging ... BIOFLOW-II substudy used intravascular ultrasound (IVUS) and optical ... and stent apposition at nine months after treating ...
(Date:5/21/2013)... Arizona State University is seeking ... develop their ideas into solutions, products and services ... university is recruiting participants for AREA48 (Applied Regional ... provides early-stage entrepreneurs with opportunities to access human ... anyone, ASU is particularly seeking participation from retirees, ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 According to ... to Rethink the Use of Botox,” Botox injections ... since their approval in 2002 (Go to goo.gl/8iYbD). Although it ... quite popular with men. The injection makes facial wrinkles less ... Botox injection last for about three months. This means that ...
(Date:5/21/2013)... The federal judge overseeing the litigation ... lawsuits in U.S. District Court, Northern District of Georgia, ... from Plaintiffs’ Counsel to conduct Ex Parte interviews with ... Order grants that request, and sets forth procedures under ... Medical Technology, Inc., Conserve Hip Implant Products Liability Litigation, ...
Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3
(Date:5/21/2013)... -- NxStage Medical, Inc. (Nasdaq: NXTM ), a ... it has entered into new agreements covering its supply ... the kidney care division of DaVita Healthcare Partners Inc. ... the use of products for home hemodialysis in ... a second amended and restated National Service Provider Agreement ...
(Date:5/21/2013)... 2013   Regulus Therapeutics Inc . ( NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... Operating Officer and Executive Vice President, Finance, will present ... Healthcare Conference on Wednesday, May 29, 2013 at 3:30 ... Westin Boston Waterfront Hotel. The presentation will ...
(Date:5/21/2013)... and PHILADELPHIA , May 21, 2013 /PRNewswire/ ... new corporate image and impressive new product developments at the ... . "After ten years of unerring focus on product literature ... the need to mark the occasion," said founding director ... have some interesting developments of benefit to our clients and ...
Breaking Medicine Technology:NxStage Announces New Agreements with DaVita 2Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3
Cached News: